In a recent study, RIPK1 activation was found in human COVID-19 lung samples.92 Treatment with Necrostatin-1(Nec1, a known RIPK1 inhibitor) reduced viral load, inflammation, and damage in cells and mouse models infected with SARS-CoV-2. The gene discussed is RIPK1; the disease is COVID-19.